ALSNCT05271435
Digital Tools for Assessment of Motor Functions and Falls in ALS
An observational study of ALS and PLS, run by Milton S. Hershey Medical Center at 1 site in United States.
Trial summary
This is a 48-week single arm study that incorporates digital tools for assessing motor function as part of an ALS telemonitoring program. During the study, neck- and wrist-worn "activity sensors" (PAMSys, BioSensics, Newton, MA) that will be worn by subjects while performing tasks of daily living. Read more about this study
- Who is it for?
- Ages 18 years and older
- What is being tested?
- PAMSys Activity Monitoring System and Motor, Speech, and Handwriting Assessment
- Type of treatment
- Pill or oral medicine, Medical device, Lifestyle or therapy programme
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Oct 2021to 25 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with motor neuron disease experiences changes in their walking.
Who may be able to join
- Diagnosis of definite, probable, probable laboratory-supported, or possible ALS by revised El Escorial research criteria [Brooks2000], primary lateral sclerosis (PLS), or progressive muscular atrophy (PMA).
- 18 years of age or older;
- ALSFRS-R walking sub-score of either 4 (normal gait), 3 (early ambulation difficulties), or 2 (walking with assistance);
- Fluent in written and spoken English.
Who cannot join
- Neurological or orthopedic problems independent of their inclusionary diagnosis that affects their gait;
- Pregnant or nursing woman;
- Prisoner or institutionalized individuals;
- Have any clinically relevant medical history of other disease or diseases that, in the opinion of the research team, exclude the subject from participation (including severe cognitive dysfunction).
Trial locations and contacts
1 site in 1 country.
United States1 site
Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033
About this study
This is a 48-week single arm study that incorporates digital tools for assessing motor function as part of an ALS telemonitoring program. During the study, neck- and wrist-worn "activity sensors" (PAMSys, BioSensics, Newton, MA) that will be worn by subjects while performing tasks of daily living. Subjects will also complete a motor, speech, and handwriting assessment during site visits. Subjects will complete a digital home assessments of speech, handwriting, and pattern tracing tasks throughout the study, and report any falls which occur on the study tablet. The investigators will explore whether functional changes are sensitive to self-reported changes on the ALS Functional Rating Scale - Revised (ALFRS-R) over the length of the study.
Read the detailed description
Many of the recognized intrinsic factors for falls are commonly seen in ALS, including advanced age, muscle weakness, gait and balance problems, and previous falls. The American Academy of Neurology ALS Quality Standards Committee recommends querying patients for falls occurring in the past 12 months, indicating that prevention of falls is an important part of disease management. Despite this, the determinants and prevention of falls in this population is critically understudied.
Among frail older adults, fallers (those who reported at least 1 fall in the last 6-months) spent more than twice as much time walking as non-fallers (those who reported no falls in the last 6-months). For these individuals, the best predictors of falling are measures related to activity exposure, such as time spent walking, average walking bout duration, or steps per day. Activity metrics of cadence variability, peak vertical acceleration variability, average duration of episodes of walking, frontal acceleration variability, average peak vertical acceleration, and average cadence have been shown to be associated with fall risk. During walking, individuals with ALS have increased and highly variable gait cycle time (time to complete a full walking cycle), along with reduced stride length with increased variability in stride length compared to healthy controls.
The ability to observe changes in gait and posture has rapidly advanced around a revolution in mobile health technology. Inertial measurement units (IMUs), a standard inclusion of nearly all new smartphone/smartwatch devices, are small electronic chips that detect different aspects of inertial change, notably linear acceleration, angular velocity, and position relative to the magnetic field of the earth. Unlike their expansive use in movement disorders like Parkinson's disease, IMU-based gait assessment has been largely absent in ALS, despite the rapid changes to gait that may occur. The standard model for assessing and acting upon functional motor changes, including those impacting gait and falls, occurs roughly once every three months when patients are seen in the outpatient setting. Furthermore, self-reporting of falls has been shown to suffer from recall bias, resulting in low sensitivity and underreporting of fall events. In summary, patients with a rapidly progressing neurodegenerative disease, who in the standard care setting receive physical assessment motor function every three months, might stand to benefit from a home-based, objective biomarker for functional motor changes.
- Being tested
- PAMSys Activity Monitoring System, Motor, Speech, and Handwriting Assessment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PAMSys Activity Monitoring SystemDevice
This system is composed of a Study Tablet running custom fall detection and reporting software and PAMSys sensors. PAMSys provides clinical-grade physical activity monitoring, storing the raw accelerometer data that can be used for analyzing activity parameters such as those listed in Table 3. Sensor data will be downloaded manually upon receipt of the study device by Biosensics, the study sponsor. Sensors can be worn during all activities including while showering and sleeping. The rated battery life is 3-6 months for the fall sensor, and 4 weeks for the activity sensors. This system is not classified as a medical device. Reports of sensor use, step number, battery level, and memory availability are sent hourly to a secured and HIPAA compliant back-end server provided by BioSensics. The Study Tablet also contains modules for performing speech, handwriting, and pattern tracing tasks.
Motor, Speech, and Handwriting AssessmentBehavioural
These assessments occur at each study visit. After equipping the subject with 3 activity sensors (1 on pendant around neck and 2 on wrists).
- 10-meter walk task (5 minutes) - The subject starts from a standing position and walks a length of 10 meters. The best time of three trials is used.
- Timed Up and Go (TUG) test (5 minutes) - Subjects stand, walk to a marker on the floor 3 meters ahead, turn around the marker, walk back to the chair, and sit. The best time of three trials is used.
- Handwriting Assessment Battery (HAB) (15 minutes) [Faddy2008] - The subject is seated at a table with a pencil and paper and performs a series of writing tasks.
- Speech Assessment Battery (SAB)(10 minutes) - The participant will perform a set of audio recordings using the study tablet while sitting in a quiet room.
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Physical Activity at 10 months
Changes in physical activity from baseline to 10 months will be assessed. Physical activity will be quantified by measuring number of taken steps per day and will be measured using a validated wearable sensor named PAMSys. Monitoring of physical activity will be done during 72 hours at baseline and 72 hours at 10 months.
Measured: baseline and visit 4 (an average of 10 months)
Secondary outcomes (25)
Change from baseline in total lower limb muscle strength at end of study
Strength testing is performed by the attending neurologist at clinical appointments. Bilateral hip flexion, knee extension and flexion, and foot dorsiflexion strength will be documented according to Medical Research Council (MRC) grade 0 (no power) to 5 (normal power). Total score for bilateral muscle groups ranges from 0 to 40. Change in total lower limb strength score over study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in total upper limb muscle strength at end of study
Strength testing is performed by the attending neurologist at clinical appointments. Bilateral deltoids, biceps, triceps, wrist extension, and interossei strength will be documented according to Medical Research Council (MRC) grade 0 (no power) to 5 (normal power). Total score for bilateral muscle groups ranges from 0 to 50. Change in total upper limb strength score over study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in total upper limb reflexes at end of study
Reflex testing is performed by the attending neurologist at clinical appointments. Bilateral biceps, triceps, and brachioradialis reflexes will be documented according to Modified Ashworth Scale grade 0 (no tone increase) to 4 (limb rigid). Total score for bilateral muscle groups ranges from 0 to 24. Change in total upper limb reflexes over study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in total lower limb reflexes at end of study
Reflex testing is performed by the attending neurologist at clinical appointments. Bilateral patellar and achilles reflexes will be documented according to Modified Ashworth Scale grade 0 (no tone increase) to 4 (limb rigid). Total score for bilateral muscle groups ranges from 0 to 16. Change in total lower limb reflexes over study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in Forced Vital Capacity at end of study
Forced vital capacity (FVC) is collected at clinical appointments. FVC is expressed as a percentage (%) of predicted volume against an age, height, and ethnicity matched standard. Change in FVC over this time period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in total ALSFRS-R at end of study
ALS Functional Rating Scale-Revised (ALSFRS-R) measures function in 12 domains. The total score ranges from 48 (normal function) to 0 (no function). Change in total score over this time period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in ALSFRS-R gross motor subscore at end of study
ALS Functional Rating Scale-Revised (ALSFRS-R) gross motor subscore measures function in 3 domains. The total subscore ranges from 12 (normal function) to 0 (no function). Change in total subscore over this time period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in ALSFRS-R fine motor subscore at end of study
ALS Functional Rating Scale-Revised (ALSFRS-R) fine motor subscore measures function in 3 domains. The total subscore ranges from 12 (normal function) to 0 (no function). Change in total subscore over this time period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in "Falls Efficacy Scale - International" total score at end of study
The Falls Efficacy Scale - International (FES-I) is collected at study visits. The total score ranges from 64 (high concern about falling) to 0 (no concern about falling). Change in total score over this time period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in "Fatigue Severity Scale" total score at end of study
The Fatigue Severity Scale is collected at study visits. The total score ranges from 63 (high fatigue) to 9 (low fatigue). Change in total score over this time period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in "Neurological Fatigue Index - Motor Neuron Disease" weakness subscale at end of study
The Neurological Fatigue Index - Motor Neuron Disease is collected at study visits. The weakness subscale total score ranges from 21 (high fatigue) to 7 (low fatigue). Change in total score over this time period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in "Neurological Fatigue Index - Motor Neuron Disease" energy subscale at end of study
The Neurological Fatigue Index - Motor Neuron Disease is collected at study visits. The energy subscale total score ranges from 18 (high fatigue) to 6 (low fatigue). Change in total score over this time period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in speaking rate at end of study
Subjects will complete the audio recording of a standard reading passage every two weeks. The speaking rate will be calculated from this audio, and the change in speaking rate over the study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in 3-meter Timed-Up-and-Go at end of study
3-meter timed-up-and-go task is recorded at study visits. The best time of three trials is recorded. Change in best time over the study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Change from baseline in 10 meter walk at end of study
A 10-meter walk task is recorded at study visits. The best time of three trials is recorded. Change in best time over the study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Handwriting Assessment: Change from baseline in handwriting speed at end of study
As part of the Handwriting Assessment Battery completed at study visits, subjects will copy a standard sentence from a prompt in the booklet. The change in writing speed for this copying task over the study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Handwriting Assessment: Change from baseline in legibility at end of study
As part of the Handwriting Assessment Battery (HAB) completed at study visits, subjects will print the alphabet in upper and lowercase, as well as the numbers 1-12. Legibility will be determined as the percent of individual characters rated as legible according to the HAB handbook. The change in character legibility over the study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Digital Handwriting Assessment: Change from baseline in handwriting speed at end of study
As part of the Digital Handwriting Assessment performed every two weeks on the study tablet, subjects will copy a standard sentence from a prompt on the tablet. The change in writing speed for this copying task over the study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Digital Handwriting Assessment: Change from baseline in legibility at end of study
As part of the Digital Handwriting Assessment performed every two weeks on the study tablet, subjects will print the alphabet in upper and lowercase, as well as the numbers 1-12. Legibility will be determined as the percent of individual characters rated as legible according to the HAB handbook. The change in character legibility over the study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Digital Handwriting Assessment: Change from baseline in spiral tracing speed at end of study
As part of the Digital Handwriting Assessment performed every two weeks on the study tablet, subjects will be timed as they trace the outline of a spiral. The change in time to complete the tracing over the study period will be calculated.
Measured: baseline and end of study (an average of 1 year)
Fall Event Detections
Fall events (falls and near-falls) detected by the sensor are registered on the study tablet. The total number of fall events registered over the course of the study is a secondary outcome.
Measured: end of study (an average of 1 year)
Fall Event Reports
Subjects enter fall event reports in the study tablet. The total number of reports reported over the course of the study is a secondary outcome
Measured: end of study (an average of 1 year)
Adherence: Tablet Assessments
Total number of assessments (handwriting, speech, and pattern tracing) completed on the tablet over the study period.
Measured: end of study (an average of 1 year)
Adherence: Fall Sensor
Total number of hours registered with wearing the fall sensor over the study period.
Measured: end of study (an average of 1 year)
Adherence: Activity Sensor
Total number of hours registered with wearing the activity sensors over the study period.
Measured: end of study (an average of 1 year)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Mar 2022
- Study start1 Oct 2021
- Primary completion25 Jun 2026
- Study completion25 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ALSStudies of the same condition, open and under way.
- More trials run by Milton S. Hershey Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Milton S. Hershey Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- BioSensics
- Responsible party
- Principal investigator, Andrew Geronimo, Milton S. Hershey Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05271435
- Sponsor's protocol ID
- STUDY13892
- Status last verified
- Jun 2026
- First submitted
- 12 Jan 2022
- Last updated
- 29 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Digital Tools for Assessment of Motor Functions and Falls in ALS
- ClinicalTrials.gov ID
- NCT05271435
- Acronym / sponsor ID
- STUDY13892
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Milton S. Hershey Medical CenterUniversity, hospital or other
- Collaborators
- BioSensics
- Study start
- 1 Oct 2021 (actual)
- Primary completion
- 25 Jun 2026 (actual)
- Study completion
- 25 Jun 2026 (actual)
- First posted
- 9 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a 48-week single arm study that incorporates digital tools for assessing motor function as part of an ALS telemonitoring program. During the study, neck- and wrist-worn "activity sensors" (PAMSys, BioSensics, Newton, MA) that will be worn by subjects while performing tasks of daily living. Subjects will also complete a motor, speech, and handwriting assessment during site visits. Subjects will complete a digital home assessments of speech, handwriting, and pattern tracing tasks throughout the study, and report any falls which occur on the study tablet. The investigators will explore whether functional changes are sensitive to self-reported changes on the ALS Functional Rating Scale - Revised (ALFRS-R) over the length of the study.
Detailed description
Many of the recognized intrinsic factors for falls are commonly seen in ALS, including advanced age, muscle weakness, gait and balance problems, and previous falls. The American Academy of Neurology ALS Quality Standards Committee recommends querying patients for falls occurring in the past 12 months, indicating that prevention of falls is an important part of disease management. Despite this, the determinants and prevention of falls in this population is critically understudied.
Among frail older adults, fallers (those who reported at least 1 fall in the last 6-months) spent more than twice as much time walking as non-fallers (those who reported no falls in the last 6-months). For these individuals, the best predictors of falling are measures related to activity exposure, such as time spent walking, average walking bout duration, or steps per day. Activity metrics of cadence variability, peak vertical acceleration variability, average duration of episodes of walking, frontal acceleration variability, average peak vertical acceleration, and average cadence have been shown to be associated with fall risk. During walking, individuals with ALS have increased and highly variable gait cycle time (time to complete a full walking cycle), along with reduced stride length with increased variability in stride length compared to healthy controls.
The ability to observe changes in gait and posture has rapidly advanced around a revolution in mobile health technology. Inertial measurement units (IMUs), a standard inclusion of nearly all new smartphone/smartwatch devices, are small electronic chips that detect different aspects of inertial change, notably linear acceleration, angular velocity, and position relative to the magnetic field of the earth. Unlike their expansive use in movement disorders like Parkinson's disease, IMU-based gait assessment has been largely absent in ALS, despite the rapid changes to gait that may occur. The standard model for assessing and acting upon functional motor changes, including those impacting gait and falls, occurs roughly once every three months when patients are seen in the outpatient setting. Furthermore, self-reporting of falls has been shown to suffer from recall bias, resulting in low sensitivity and underreporting of fall events. In summary, patients with a rapidly progressing neurodegenerative disease, who in the standard care setting receive physical assessment motor function every three months, might stand to benefit from a home-based, objective biomarker for functional motor changes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with motor neuron disease experiences changes in their walking.
Key inclusion criteria (4 listed)
- Diagnosis of definite, probable, probable laboratory-supported, or possible ALS by revised El Escorial research criteria [Brooks2000], primary lateral sclerosis (PLS), or progressive muscular atrophy (PMA).
- 18 years of age or older;
- ALSFRS-R walking sub-score of either 4 (normal gait), 3 (early ambulation difficulties), or 2 (walking with assistance);
- Fluent in written and spoken English.
Key exclusion criteria (4 listed)
- Neurological or orthopedic problems independent of their inclusionary diagnosis that affects their gait;
- Pregnant or nursing woman;
- Prisoner or institutionalized individuals;
- Have any clinically relevant medical history of other disease or diseases that, in the opinion of the research team, exclude the subject from participation (including severe cognitive dysfunction).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PAMSys Activity Monitoring SystemThis system is composed of a Study Tablet running custom fall detection and reporting software and PAMSys sensors. PAMSys provides clinical-grade physical activity monitoring, storing the raw accelerometer data that can be used for analyzing activity parameters such as those listed in Table 3. Sensor data will be downloaded manually upon receipt of the study device by Biosensics, the study sponsor. Sensors can be worn during all activities including while showering and sleeping. The rated battery life is 3-6 months for the fall sensor, and 4 weeks for the activity sensors. This system is not classified as a medical device. Reports of sensor use, step number, battery level, and memory availability are sent hourly to a secured and HIPAA compliant back-end server provided by BioSensics. The Study Tablet also contains modules for performing speech, handwriting, and pattern tracing tasks. | Device | – |
| Motor, Speech, and Handwriting AssessmentThese assessments occur at each study visit. After equipping the subject with 3 activity sensors (1 on pendant around neck and 2 on wrists). * 10-meter walk task (5 minutes) - The subject starts from a standing position and walks a length of 10 meters. The best time of three trials is used. * Timed Up and Go (TUG) test (5 minutes) - Subjects stand, walk to a marker on the floor 3 meters ahead, turn around the marker, walk back to the chair, and sit. The best time of three trials is used. * Handwriting Assessment Battery (HAB) (15 minutes) [Faddy2008] - The subject is seated at a table with a pencil and paper and performs a series of writing tasks. * Speech Assessment Battery (SAB)(10 minutes) - The participant will perform a set of audio recordings using the study tablet while sitting in a quiet room. | Behavioural | – |
Primary outcome
Change in Physical Activity at 10 months
Time frame: baseline and visit 4 (an average of 10 months)
Changes in physical activity from baseline to 10 months will be assessed. Physical activity will be quantified by measuring number of taken steps per day and will be measured using a validated wearable sensor named PAMSys. Monitoring of physical activity will be done during 72 hours at baseline and 72 hours at 10 months.
25 secondary outcomes
Change from baseline in total lower limb muscle strength at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in total upper limb muscle strength at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in total upper limb reflexes at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in total lower limb reflexes at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in Forced Vital Capacity at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in total ALSFRS-R at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in ALSFRS-R gross motor subscore at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in ALSFRS-R fine motor subscore at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in "Falls Efficacy Scale - International" total score at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in "Fatigue Severity Scale" total score at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in "Neurological Fatigue Index - Motor Neuron Disease" weakness subscale at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in "Neurological Fatigue Index - Motor Neuron Disease" energy subscale at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in speaking rate at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in 3-meter Timed-Up-and-Go at end of study
Time frame: baseline and end of study (an average of 1 year)
Change from baseline in 10 meter walk at end of study
Time frame: baseline and end of study (an average of 1 year)
Handwriting Assessment: Change from baseline in handwriting speed at end of study
Time frame: baseline and end of study (an average of 1 year)
Handwriting Assessment: Change from baseline in legibility at end of study
Time frame: baseline and end of study (an average of 1 year)
Digital Handwriting Assessment: Change from baseline in handwriting speed at end of study
Time frame: baseline and end of study (an average of 1 year)
Digital Handwriting Assessment: Change from baseline in legibility at end of study
Time frame: baseline and end of study (an average of 1 year)
Digital Handwriting Assessment: Change from baseline in spiral tracing speed at end of study
Time frame: baseline and end of study (an average of 1 year)
Fall Event Detections
Time frame: end of study (an average of 1 year)
Fall Event Reports
Time frame: end of study (an average of 1 year)
Adherence: Tablet Assessments
Time frame: end of study (an average of 1 year)
Adherence: Fall Sensor
Time frame: end of study (an average of 1 year)
Adherence: Activity Sensor
Time frame: end of study (an average of 1 year)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for ALS
RecruitingPhase 1/2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Amyotrophic Lateral Sclerosis
Not yet recruiting
A Study on the Addition of Alsum30 for the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), Bacillus Coagulans
Active, not recruiting
Functional Outcomes and Control Using Synchron BCI - Australia
Neurologic Disorder, Neurologic Diseases
Not yet recruitingPhase 1
Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Recruiting
Clinical Outcome Assessment for AT & BCI
Spinal Cord Injury, ALS (Amyotrophic Lateral Sclerosis)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of ALS and PLS, run by Milton S. Hershey Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Physical Activity at 10 months (time frame: baseline and visit 4 (an average of 10 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.